CoChat
Sign Up
Cited by 351Genomics and Chromatin DynamicsDNA Repair MechanismsEpigenetics and DNA Methylation

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Screen for DNA‐damage‐responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells

Open access
Tjeertes, Jorrit V, Miller, Kyle M, Jackson, Stephen P·2009·The EMBO Journal
DOI 10.1038/emboj.2009.119PMC PMC2684025
Open this paper in CoChat — free accountOpen PDF

Abstract

Recognition and repair of damaged DNA occurs within the context of chromatin. The key protein components of chromatin are histones, whose post-translational modifications control diverse chromatin functions. Here, we report our findings from a large-scale screen for DNA-damage-responsive histone modifications in human cells. We have identified specific phosphorylations and acetylations on histone H3 that decrease in response to DNA damage. Significantly, we find that DNA-damage-induced changes in H3S10p, H3S28p and H3.3S31p are a consequence of cell-cycle re-positioning rather than DNA damage per se. In contrast, H3K9Ac and H3K56Ac, a mark previously uncharacterized in human cells, are rapidly and reversibly reduced in response to DNA damage. Finally, we show that the histone acetyl-transferase GCN5/KAT2A acetylates H3K56 in vitro and in vivo. Collectively, our data indicate that though most histone modifications do not change appreciably after genotoxic stress, H3K9Ac and H3K56Ac are reduced in response to DNA damage in human cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emboj.2009.119

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Screen for DNA-damage-responsive histone modifications. (A) U2OS cells were untreated (Untr) or treated with 2 mM HU for 24 h or with 60 μg/ml phleomycin (Phleo) for 2 h. Cells were split into two samples, one being used for the acid extraction of histones that were analysed in (B) and one sample for whole cell Laemmli extracts, which were analysed by western blotting with the indicated antibodies in (A). (B) Coomassie staining of recombinant histones (Rec) and acid-extracted histones from either untreated (Untr), HU-treated or phleo-treated U2OS cells. (C) Antibody-based screen for DNA-damage-responsive histone PTMs. Samples from (B) were used for western blot analysis with the antibodies described in Supplementary Table 1. The results were categorized as described in the text.
Figure 1 Screen for DNA-damage-responsive histone modifications. (A) U2OS cells were untreated (Untr) or treated with 2 mM HU for 24 h or with 60 μg/ml phleomycin (Phleo) for 2 h. Cells were split into two samples, one being used for the acid extraction of histones that were analysed in (B) and one sample for whole cell Laemmli extracts, which were analysed by western blotting with the indicated antibodies in (A). (B) Coomassie staining of recombinant histones (Rec) and acid-extracted histones from either untreated (Untr), HU-treated or phleo-treated U2OS cells. (C) Antibody-based screen for DNA-damage-responsive histone PTMs. Samples from (B) were used for western blot analysis with the antibodies described in Supplementary Table 1. The results were categorized as described in the text.CC BY-NC-ND · PubMed Central
Figure 2 Analysis of DDR-responsive histone PTMs. (A) Analysis of histone PTMs in U2OS or Hela cells. Left panels, U2OS cells were treated with the indicated DNA-damaging agents (see Materials and methods for details) and analysed by western blotting of whole cell Laemmli extracts with the indicated antibodies. Right panels, Hela cells were untreated or treated with 60 μg/ml of phleomycin and analysed as described for U2OS cells. (B) Cell-cycle analysis of histone PTMs. U2OS cells were synchronized at the G1/S-transition by a double-thymidine procedure and subsequently released into the cell cycle. Samples were taken at indicated time points and cell-cycle distributions were determined by FACS analyses. A sample from asynchronous (Asyn) cells is shown as a control. These samples were additionally subjected to western blot analyses of whole cell Laemmli extracts and probed with the indicated antibodies.
Figure 2 Analysis of DDR-responsive histone PTMs. (A) Analysis of histone PTMs in U2OS or Hela cells. Left panels, U2OS cells were treated with the indicated DNA-damaging agents (see Materials and methods for details) and analysed by western blotting of whole cell Laemmli extracts with the indicated antibodies. Right panels, Hela cells were untreated or treated with 60 μg/ml of phleomycin and analysed as described for U2OS cells. (B) Cell-cycle analysis of histone PTMs. U2OS cells were synchronized at the G1/S-transition by a double-thymidine procedure and subsequently released into the cell cycle. Samples were taken at indicated time points and cell-cycle distributions were determined by FACS analyses. A sample from asynchronous (Asyn) cells is shown as a control. These samples were additionally subjected to western blot analyses of whole cell Laemmli extracts and probed with the indicated antibodies.CC BY-NC-ND · PubMed Central
Figure 3 Mitotic H3 phosphorylations are unaltered by DNA damage. (A) H3 phosphorylation levels, but not acetylation levels, are unaffected by DNA damage. U2OS cells were arrested in pro-metaphase with nocodazole, then were either kept in nocodazole (Noc; M-phase) or released from nocodazole for 6 h (Noc & Rel; G1/S-phase) and subsequently either mock or phleomycin treated. Samples were analysed as in Figure 2. (B) Immunofluorescence analysis of H3 phosphorylations in mitosis. Nocodazole-arrested U2OS cells were left untreated or treated with phleomycin and analysed by immunofluorescence with the indicated antibodies. Induction of DNA damage was visualized by γH2AX staining and the nucleus by DAPI staining of DNA. (C) Analysis of H3S10p and H3T11p in interphase cells. U2OS cells were untreated or treated for 2 h with phleomycin and analysed by immunofluorescence for H3S10p and H3T11p. The enlarged section depicts punctuate co-localized staining of H3S10p and H3T11p. Note the loss of brightly stained mitotic cells in phleomycin-treated cell populations. (D) H3T11p is unaffected in cells containing concentrated tracks of DNA damage. U2OS cells were microirradiated to induce tracks containing DNA damage. Cells were allowed to recover for 2 h before fixation and subsequent dual staining for 53BP1 and H3T11p. Inset shows a zoomed section of the damaged area.
Figure 3 Mitotic H3 phosphorylations are unaltered by DNA damage. (A) H3 phosphorylation levels, but not acetylation levels, are unaffected by DNA damage. U2OS cells were arrested in pro-metaphase with nocodazole, then were either kept in nocodazole (Noc; M-phase) or released from nocodazole for 6 h (Noc & Rel; G1/S-phase) and subsequently either mock or phleomycin treated. Samples were analysed as in Figure 2. (B) Immunofluorescence analysis of H3 phosphorylations in mitosis. Nocodazole-arrested U2OS cells were left untreated or treated with phleomycin and analysed by immunofluorescence with the indicated antibodies. Induction of DNA damage was visualized by γH2AX staining and the nucleus by DAPI staining of DNA. (C) Analysis of H3S10p and H3T11p in interphase cells. U2OS cells were untreated or treated for 2 h with phleomycin and analysed by immunofluorescence for H3S10p and H3T11p. The enlarged section depicts punctuate co-localized staining of H3S10p and H3T11p. Note the loss of brightly stained mitotic cells in phleomycin-treated cell populations. (D) H3T11p is unaffected in cells containing concentrated tracks of DNA damage. U2OS cells were microirradiated to induce tracks containing DNA damage. Cells were allowed to recover for 2 h before fixation and subsequent dual staining for 53BP1 and H3T11p. Inset shows a zoomed section of the damaged area.CC BY-NC-ND · PubMed Central
Figure 4 H3K9Ac and H3K56Ac decrease rapidly and reversibly upon DNA damage. (A) Transcriptional inhibition does not affect H3K9Ac and H3K56Ac levels. Cells were treated for 2 h with DRB, a Pol II transcription inhibitor, and analysed for H3K9Ac and H3K56Ac as described for Figure 2. (B) Dynamics of changes in H3K9Ac and H3K56Ac levels are reciprocal to those of γH2AX. Recovery dynamics of H3K9Ac and H3K56Ac levels were measured by acute treatment of U2OS cells with phleomycin for 2 h and subsequently releasing them into phleomycin-free medium. Samples were taken at the indicated time points and analysed using whole cell Laemmli extracts with the indicated antibodies. H3K14Ac was included to control for a DDR-independent histone acetylation, γH2AX to detect DNA-damage induction and H3 for loading. (C) H3K9Ac and H3K56Ac levels decrease rapidly upon DNA damage. U2OS cells were chronically treated with phleomycin and samples were taken at the indicated times and analysed as in A. (D) PIKK inhibition reduces H3K9 and H3K56 acetylation. U2OS cells were pre-incubated for 1 h with or without KU-55933, or wortmannin, then analysed as in A. (E) H3K56Ac levels are reduced at promoters of cell-cycle regulatory genes upon DNA damage. Schematic representation of CYCLIN B1 and CDK1 genes showing positions analysed by ChIP followed by real-time qPCR. U2OS cells were untreated or treated with phleomycin or 2 h, before analyses by ChIP. Data represents percentage of IPed H3K56Ac signal normalized to IPed H3 signal at the indicated genomic loci. Data represent the average of three independent experiments and error bars show the standard deviation between these experiments.
Figure 4 H3K9Ac and H3K56Ac decrease rapidly and reversibly upon DNA damage. (A) Transcriptional inhibition does not affect H3K9Ac and H3K56Ac levels. Cells were treated for 2 h with DRB, a Pol II transcription inhibitor, and analysed for H3K9Ac and H3K56Ac as described for Figure 2. (B) Dynamics of changes in H3K9Ac and H3K56Ac levels are reciprocal to those of γH2AX. Recovery dynamics of H3K9Ac and H3K56Ac levels were measured by acute treatment of U2OS cells with phleomycin for 2 h and subsequently releasing them into phleomycin-free medium. Samples were taken at the indicated time points and analysed using whole cell Laemmli extracts with the indicated antibodies. H3K14Ac was included to control for a DDR-independent histone acetylation, γH2AX to detect DNA-damage induction and H3 for loading. (C) H3K9Ac and H3K56Ac levels decrease rapidly upon DNA damage. U2OS cells were chronically treated with phleomycin and samples were taken at the indicated times and analysed as in A. (D) PIKK inhibition reduces H3K9 and H3K56 acetylation. U2OS cells were pre-incubated for 1 h with or without KU-55933, or wortmannin, then analysed as in A. (E) H3K56Ac levels are reduced at promoters of cell-cycle regulatory genes upon DNA damage. Schematic representation of CYCLIN B1 and CDK1 genes showing positions analysed by ChIP followed by real-time qPCR. U2OS cells were untreated or treated with phleomycin or 2 h, before analyses by ChIP. Data represents percentage of IPed H3K56Ac signal normalized to IPed H3 signal at the indicated genomic loci. Data represent the average of three independent experiments and error bars show the standard deviation between these experiments.CC BY-NC-ND · PubMed Central
Figure 5 hGCN5 acetylates H3K9 and H3K56 in vitro and in vivo. (A) The H3K9 and H3K56 motifs share sequence similarity. (B) Human GCN5 acetylates H3K9 and H3K56 in vitro. HAT activity towards H3K9 and H3K56 was assessed with purified S. cerevisiae and S. pombe Rtt109 (ScRTT109 and SpRTT109, respectively) or human GCN5 (hGCN5) in an in vitro HAT-assay containing purified human recombinant histone H3.1 (Rec. H3) with subsequent analysis by western blotting with the indicated antibodies. SpClr4 was used as a non-HAT enzyme and a ponceau staining of Rec. H3 is shown as a loading control. (C) H3K9Ac antibody is specific. Purified SpRtt109 was incubated with Rec.H3 or Rec. H3 containing a Lys9 to Ala mutation (H3K9A) and analysed as in A. (D) H3K56Ac antibody is specific. Experiments were done as in B except Rec. H3K56A was used instead of Rec. H3K9A. (E) hGCN5 is involved in acetylation of H3K9 and H3K56 in vivo. U2OS cells were transfected with siRNAs against luciferase (siLuc) or GCN5 (siGCN5) and samples were analysed after 48 h by western blotting of whole cell Laemmli extracts with the indicated antibodies. (F) GCN5 depletion leads to the loss of H3K56Ac at promoters of cell-cycle regulatory genes. U2OS cells were transfected as in E and analysed as in Figure 4E.
Figure 5 hGCN5 acetylates H3K9 and H3K56 in vitro and in vivo. (A) The H3K9 and H3K56 motifs share sequence similarity. (B) Human GCN5 acetylates H3K9 and H3K56 in vitro. HAT activity towards H3K9 and H3K56 was assessed with purified S. cerevisiae and S. pombe Rtt109 (ScRTT109 and SpRTT109, respectively) or human GCN5 (hGCN5) in an in vitro HAT-assay containing purified human recombinant histone H3.1 (Rec. H3) with subsequent analysis by western blotting with the indicated antibodies. SpClr4 was used as a non-HAT enzyme and a ponceau staining of Rec. H3 is shown as a loading control. (C) H3K9Ac antibody is specific. Purified SpRtt109 was incubated with Rec.H3 or Rec. H3 containing a Lys9 to Ala mutation (H3K9A) and analysed as in A. (D) H3K56Ac antibody is specific. Experiments were done as in B except Rec. H3K56A was used instead of Rec. H3K9A. (E) hGCN5 is involved in acetylation of H3K9 and H3K56 in vivo. U2OS cells were transfected with siRNAs against luciferase (siLuc) or GCN5 (siGCN5) and samples were analysed after 48 h by western blotting of whole cell Laemmli extracts with the indicated antibodies. (F) GCN5 depletion leads to the loss of H3K56Ac at promoters of cell-cycle regulatory genes. U2OS cells were transfected as in E and analysed as in Figure 4E.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

Sorted by citations

Items 301–351 of 351

Related

See all

Metadata

Authors
Tjeertes, J. V., Miller, K. M., & Jackson, S. P.
Affiliations
University of Cambridge (GB)
Corresponding author
  • Miller, Kyle M
  • Jackson, Stephen P
ORCID
Venue
The EMBO Journal
Publisher
Springer Science and Business Media LLC
Published
2009-04-30
Volume
28
Issue
13
Pages
1878-1889
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
DOI
10.1038/emboj.2009.119
PMC
PMC2684025
OpenAlex
W2046691617
Cited by
347
References
68
Citations by year
2026: 7 · 2025: 10 · 2024: 21 · 2023: 15 · 2022: 16 · 2021: 18 · 2020: 14 · 2019: 17 · 2018: 13 · 2017: 21 · 2016: 21 · 2015: 22 · 2014: 20 · 2013: 31 · 2012: 31
FWCI
13.54
Type
journal article
Language
en
Open access
Licence
Locations
  • The EMBO Journal (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Wellcome Trust (086861/Z/08/Z, 086861)
  • Cancer Research UK (A5290)
  • Directorate for Biological Sciences
  • Biotechnology and Biological Sciences Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
DNA damage response, histone modifications, H3K9 acetylation, H3K56 acetylation, histone acetylation, histone phosphorylation, histone acetyltransferase, chromatin, genotoxic stress
MeSH terms
p300-CBP-Associated Factor, Acetylation, Cell Cycle, DNA Damage, DNA Repair, HeLa Cells, Histones, Humans, Phosphorylation, Protein Processing, Post-Translational, Histone Code, Cell Line, Tumor, Histone Acetyltransferases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review